BACTEK™ (MV130) is a novel bacterial sublingual immunotherapy for the prevention of recurrent respiratory tract infections (RTIs). The product was developed by Inmunotek, an innovative pharmaceutical company based in Spain, and is exclusively licensed in Canada to Red Leaf Medical.

BACTEK™ is currently in clinical trials. Red Leaf Medical intends to bring BACTEK™ to the Canadian market when the appropriate availability of clinical data supports a submission.